Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Huntington National Bank

Huntington National Bank grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.8% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 605 shares of the biopharmaceutical company’s stock after buying an additional 33 shares during the quarter. Huntington National Bank’s holdings in Regeneron Pharmaceuticals were worth $636,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Quent Capital LLC lifted its stake in shares of Regeneron Pharmaceuticals by 5.1% in the first quarter. Quent Capital LLC now owns 390 shares of the biopharmaceutical company’s stock worth $375,000 after buying an additional 19 shares in the last quarter. Acadian Asset Management LLC lifted its stake in Regeneron Pharmaceuticals by 37.2% in the 1st quarter. Acadian Asset Management LLC now owns 62,141 shares of the biopharmaceutical company’s stock worth $59,794,000 after purchasing an additional 16,856 shares in the last quarter. Jacobi Capital Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 1.8% during the 1st quarter. Jacobi Capital Management LLC now owns 1,139 shares of the biopharmaceutical company’s stock worth $1,096,000 after purchasing an additional 20 shares during the last quarter. Covestor Ltd grew its position in shares of Regeneron Pharmaceuticals by 7.4% in the first quarter. Covestor Ltd now owns 202 shares of the biopharmaceutical company’s stock valued at $195,000 after purchasing an additional 14 shares in the last quarter. Finally, O Shaughnessy Asset Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 17.5% in the first quarter. O Shaughnessy Asset Management LLC now owns 6,920 shares of the biopharmaceutical company’s stock valued at $6,660,000 after purchasing an additional 1,030 shares during the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

REGN has been the topic of a number of recent research reports. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. BMO Capital Markets dropped their price objective on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a report on Friday, November 1st. Morgan Stanley reduced their target price on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. JPMorgan Chase & Co. cut their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a report on Thursday, October 24th. Finally, Citigroup started coverage on Regeneron Pharmaceuticals in a research note on Thursday. They set a “neutral” rating and a $895.00 target price for the company. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1,099.55.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. The trade was a 27.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 7.48% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Stock Down 3.3 %

Regeneron Pharmaceuticals stock opened at $756.81 on Friday. The firm has a market capitalization of $83.17 billion, a P/E ratio of 18.73, a P/E/G ratio of 3.04 and a beta of 0.15. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a twelve month low of $753.69 and a twelve month high of $1,211.20. The stock’s fifty day simple moving average is $985.21 and its 200-day simple moving average is $1,032.97.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.